LivingGLP1
Study S002638

Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity in the Department of Health of Valencia Clínico-Malvarrosa

ClinicalTrials.gov record

Registration

Registration
NCT05535322
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
26944
Start
2014-01-01
Primary completion
2019-12-31
Lead sponsor
Ana Palanca
Conditions
Type 2 Diabetes; Obesity
Interventions
DRUG:GLP-1RA; DRUG:SGLT2i; DRUG:Insulin; DRUG:Miscellany
Results posted
FALSE
Individual participant data sharing
UNDECIDED

Registered primary outcomes

  • Major acute cardiovascular events [From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.]

Linked records (15)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0012546Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes.
Palanca A, Diabetes therapy : research, treatment and education of diabetes and related disorders
2023Nonrandomized studyPMID 36847952DOIcites ClinicalTrials.gov:NCT05535322; registry reference DERIVED:36847952
R0006812The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
Leiter LA, Diabetes, obesity & metabolism
2020OtherPMID 32372454DOIregistry reference BACKGROUND:32372454
R0009139Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study.
Pasternak B, Diabetes care
2020Nonrandomized studyPMID 32295809DOIregistry reference BACKGROUND:32295809
R0009450Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.
Pineda ED, Journal of managed care & specialty pharmacy
2020Nonrandomized studyPMID 32347181DOIregistry reference BACKGROUND:32347181
R0015805Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy.
Fadini GP, Acta diabetologica
2020Nonrandomized studyPMID 31673896DOIregistry reference BACKGROUND:31673896
R0008245Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings.
Guerci B, Diabetes & metabolism
2019Randomized trialPMID 30677504DOIregistry reference BACKGROUND:30677504
R0009358GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
Divino V, Diabetes therapy : research, treatment and education of diabetes and related disorders
2019Nonrandomized studyPMID 31028689DOIregistry reference BACKGROUND:31028689
R0012365Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL, The lancet. Diabetes & endocrinology
2019Systematic reviewPMID 31422062DOIregistry reference BACKGROUND:31422062
R0010419What have we learnt from "real world" data, observational studies and meta-analyses.
Chatterjee S, Diabetes, obesity & metabolism
2018Systematic reviewPMID 29364585DOIregistry reference BACKGROUND:29364585
R0012223Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF, Lancet (London, England)
2018Randomized trialPMID 30291013DOIregistry reference BACKGROUND:30291013
R0012259Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.
Blonde L, Diabetes therapy : research, treatment and education of diabetes and related disorders
2018Nonrandomized studyPMID 29675797DOIregistry reference BACKGROUND:29675797
R0010827Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.
Lin J, ClinicoEconomics and outcomes research : CEOR
2017Nonrandomized studyPMID 28053550DOIregistry reference BACKGROUND:28053550
R0011618GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
Divino V, Diabetes therapy : research, treatment and education of diabetes and related disorders
2017Nonrandomized studyPMID 28070733DOIregistry reference BACKGROUND:28070733
R0014195Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.
Carls GS, Diabetes care
2017Randomized trialPMID 28801475DOIregistry reference BACKGROUND:28801475
R0019155Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain.
Conget I, BMJ open
2016Nonrandomized studyPMID 27466235DOIregistry reference BACKGROUND:27466235